K. Shimada

458 total citations
28 papers, 351 citations indexed

About

K. Shimada is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, K. Shimada has authored 28 papers receiving a total of 351 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Surgery, 11 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in K. Shimada's work include Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). K. Shimada is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). K. Shimada collaborates with scholars based in Japan, United Kingdom and United States. K. Shimada's co-authors include Yukihiro Endo, Katsuhiro Uzawa, Hidetaka Yokoe, Masaki Kato, Masashi Shiiba, H Tanzawa, Naohiko Seki, Hiroki Bukawa, T Kosuge and M Makuuchi and has published in prestigious journals such as British Journal of Cancer, Annals of Oncology and Clinical Pharmacology & Therapeutics.

In The Last Decade

K. Shimada

25 papers receiving 335 citations

Peers

K. Shimada

ONCOL

PRM

SURGE

Marko Kornmann Germany

Shi‐Xun Lu China

Ganxun Li China

Anh Tuan Huynh Austria

Rie Nakatsuka Japan

Mu Yan Cai China

Baobing Yin China

Isaya Hashimoto Japan

Ryuji Okuyama Japan

Marko Kornmann Germany

K. Shimada

178 ×1.1

ONCOL

63 ×0.5

PRM

70 ×0.6

SURGE

179 ×1.8

20 ×0.4

Citations per year, relative to K. Shimada K. Shimada (= 1×) peers Marko Kornmann

Countries citing papers authored by K. Shimada

Since Specialization

Citations

This map shows the geographic impact of K. Shimada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Shimada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Shimada more than expected).

Fields of papers citing papers by K. Shimada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Shimada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Shimada. The network helps show where K. Shimada may publish in the future.

Co-authorship network of co-authors of K. Shimada

This figure shows the co-authorship network connecting the top 25 collaborators of K. Shimada. A scholar is included among the top collaborators of K. Shimada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Shimada. K. Shimada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Iguchi‐Manaka, Akiko, Bryan J. Mathis, K. Shimada, et al.. (2025). Refining compression therapy for the prevention of chemotherapy-induced peripheral neuropathy in breast cancer patients: a sub-analysis of patient-reported discomfort and usability. BMC Cancer. 25(1). 1567–1567.

Iguchi‐Manaka, Akiko, K. Shimada, Bryan J. Mathis, et al.. (2025). Paclitaxel-induced Peripheral Neuropathy and Quality of Life: Sub-analysis of the MICHEL Study. Anticancer Research. 45(9). 3827–3833.

Nishikawa, Kazuhiro, Wasaburo Koizumi, Takeharu Yamanaka, et al.. (2018). Meta-analysis of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer. Annals of Oncology. 29. viii228–viii228. 1 indexed citations

Komatsu, Yoshito, Atsuo Takashima, Tadamichi Denda, et al.. (2017). Treatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer. Annals of Oncology. 28. v158–v158. 4 indexed citations

Yamada, Yasuhide, Tadamichi Denda, Makio Gamoh, et al.. (2017). S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. Annals of Oncology. 29(3). 624–631. 55 indexed citations

Sunakawa, Yu, Shu Cao, Martin D. Berger, et al.. (2015). Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer. The Pharmacogenomics Journal. 17(1). 36–41. 11 indexed citations

Ueno, Masayuki, Takuji Okusaka, Yasushi Omuro, et al.. (2015). A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Annals of Oncology. 27(3). 502–508. 31 indexed citations

Onishi, Hideki, M. Ishida, Keisuke Miwa, et al.. (2012). Hypomanic Episode During Recurrent Gastric Cancer Treatment: Report of a Rare Case and Literature Review. Japanese Journal of Clinical Oncology. 42(10). 961–964. 4 indexed citations

Baba, Hideo, Rui‐Hua Xu, Jian Xu, et al.. (2012). Phase II Study of S-1 Plus Leucovorin (New 1 Week Treatment Regimen Followed by 1 Week Rest Period) in Patients with Untreated Metastatic Colorectal Cancer in Japan and China. Annals of Oncology. 23. xi129–xi129. 1 indexed citations

10.

Yamamoto, Yusuke, Hidenori Ojima, K. Shimada, et al.. (2009). Long-term Recurrence-free Survival in a Patient with Primary Hepatic Carcinosarcoma: Case Report with a Literature Review. Japanese Journal of Clinical Oncology. 40(2). 166–173. 21 indexed citations

11.

Sugano, Naoyuki, et al.. (2009). Protease‐activated receptor 2 mediates interleukin‐8 and intercellular adhesion molecule‐1 expression in response to Aggregatibacter actinomycetemcomitans. Oral Microbiology and Immunology. 24(4). 285–291. 9 indexed citations

12.

Shimada, K., Shingen Misaka, Dongmei Yan, et al.. (2006). PI-23Influences of CYP2C9 genotype on pharmacokinetics and pharmacodynamics of benzbromarone. Clinical Pharmacology & Therapeutics. 79(2). P13–P13. 1 indexed citations

13.

Shimada, K., Katsuhiro Uzawa, Masaki Kato, et al.. (2005). Aberrant expression of RAB1A in human tongue cancer. British Journal of Cancer. 92(10). 1915–1921. 115 indexed citations

14.

Ota, Takayo, Tatsuya Takayama, Yasumitsu Moriya, et al.. (1996). Successful Radical Surgery for an Undifferentiated Gallbladder Carcinoma with Lymph Node Metastases to the Mesocolon. Japanese Journal of Clinical Oncology. 26(6). 484–487. 2 indexed citations

15.

Konishi, Yutaka, K. Shimada, Hitoshi Tochio, et al.. (1992). Color Doppler echography of breast diseases: Detection rate of color flow signals and significance of color Doppler echography in breast diseases. 19(5). 19–26. 1 indexed citations

16.

Kudo, Masatoshi, Hitoshi Tochio, K. Shimada, et al.. (1992). Color Doppler flow imaging of hepatic focal nodular hyperplasia. Journal of Ultrasound in Medicine. 11(10). 553–557. 10 indexed citations

17.

Kosuge, T, et al.. (1992). [Effectiveness of intraoperative cytological examination of peritoneal washings for patients with pancreatic cancer].. PubMed. 93(11). 1410–5. 5 indexed citations

18.

Itoh, T., et al.. (1990). Nonoperative removal of bilateral intrahepatic biliary stones by endoscopic electrohydraulic lithotripsy.. PubMed. 85(9). 1168–71. 12 indexed citations

19.

Shimada, K., et al.. (1989). [Water and electrolyte metabolism in the elderly with cardiovascular disease--hormonal aspects in elderly hypertension].. PubMed. 26(3). 228–32. 1 indexed citations

20.

Oka, Shinichi, et al.. (1989). [Clinical evaluation of fluconazole].. PubMed. 42(1). 31–9. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact